EBMT_Cellular_Therapy (@theebmt_ctiwp) 's Twitter Profile
EBMT_Cellular_Therapy

@theebmt_ctiwp

EBMT working party on cellular therapy and immunobiology. CTIWP Chair Annalisa Ruggeri, MD, PhD, CIC 813, vicechair Jurgen Kuball, secretary Florent Malard

ID: 3361663613

calendar_today06-07-2015 01:57:07

5,5K Tweet

2,2K Followers

194 Following

Jurgen Kuball (@jkuball) 's Twitter Profile Photo

One day after world blood cancer day: stamina and world wide networks to advance are field are rewarded: Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort sciencedirect.com/science/articlโ€ฆ

Jurgen Kuball (@jkuball) 's Twitter Profile Photo

Last days of a survey of โฆGoCART_Coalitionโฉ โฆT2EVOLVEโฉ โฆEBMT_Cellular_Therapyโฉ on the needs for ATMP development. Which system or sensors we need, viral or non viral? One participant per hospital / company needed. surveymonkey.com/r/ATMPfacilitiโ€ฆ

The EBMT (@theebmt) 's Twitter Profile Photo

โบ๏ธ Live from ๐Ÿ“ Milan: We have just opened the joint meeting of Immunology and Cellular Therapies in Autoimmune Diseases! ๐Ÿ’ก During the next few days, this event hosted by the Autoimmune Diseases Working Party (ADWP) and the Cellular Therapy and Immunobiology Working Party

โบ๏ธ Live from ๐Ÿ“ Milan: We have just opened the joint meeting of Immunology and Cellular Therapies in Autoimmune Diseases!

๐Ÿ’ก During the next few days, this event hosted by the Autoimmune Diseases Working Party (ADWP) and the Cellular Therapy and Immunobiology Working Party
EBMT_Cellular_Therapy (@theebmt_ctiwp) 's Twitter Profile Photo

Joined meeting in Milano CART in auto immune diseases and finally a joined picture of our amazing team ๐Ÿ˜€ โฆAnnalisa Ruggeriโฉ โฆJurgen Kuballโฉ โฆFlorent Malardโฉ โฆSimona Pagliucaโฉ

Joined meeting in Milano CART in auto immune diseases and finally a joined picture of our amazing team ๐Ÿ˜€ โฆ<a href="/AnnalisaRugger1/">Annalisa Ruggeri</a>โฉ โฆ<a href="/JKuball/">Jurgen Kuball</a>โฉ โฆ<a href="/Florent_Malard/">Florent Malard</a>โฉ โฆ<a href="/pagliuca_simona/">Simona Pagliuca</a>โฉ
raffaellagreco (@raffaellagrecom) 's Twitter Profile Photo

Great ADWP & CTIWP joint meeting in Milano on innovative cellular therapies and #CARTcells in #autoimmunediseases. Starting a new era together! Thanks to all the speakers, chairs and attendees. The EBMT EBMT_Cellular_Therapy Annalisa Ruggeri Elisa Roldan Jurgen Kuball

Great ADWP &amp; CTIWP joint meeting in Milano on innovative cellular therapies and #CARTcells in #autoimmunediseases. Starting a new era together! Thanks to all the speakers, chairs and attendees. <a href="/TheEBMT/">The EBMT</a> <a href="/TheEBMT_CTIWP/">EBMT_Cellular_Therapy</a> <a href="/AnnalisaRugger1/">Annalisa Ruggeri</a> <a href="/elirolga/">Elisa Roldan</a> <a href="/JKuball/">Jurgen Kuball</a>
The EBMT (@theebmt) 's Twitter Profile Photo

The 1st Joint Educational Meeting of the Autoimmune Diseases & EBMT_Cellular_Therapy Working Parties in Milan was a success! ๐Ÿ‘ The event brought together top experts and a broad international audience to discuss advances in cellular therapies, particularly CAR-T, in relation to

The 1st Joint Educational Meeting of the Autoimmune Diseases &amp; <a href="/TheEBMT_CTIWP/">EBMT_Cellular_Therapy</a> Working Parties in Milan was a success! ๐Ÿ‘ The event brought together top experts and a broad international audience to discuss advances in cellular therapies, particularly CAR-T, in relation to
Institute for Experimental Cell Therapy, UK-Essen (@iztfe) 's Twitter Profile Photo

Indeed a very exciting event, which combined with the EBMT_Cellular_Therapy Scientific Business Meeting, gave us the opportuity to hear about and discuss the advances and upcoming research in HCT and cellular therapies The EBMT from an immunobiological and immunogenetic point of view.

The EBMT (@theebmt) 's Twitter Profile Photo

๐Ÿ”Ž Have you seen this publication in Bone Marrow Transplantation? ๐Ÿ“ฐ Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working

The EBMT (@theebmt) 's Twitter Profile Photo

๐ŸงตTwitter Thread:๐Ÿงต EBMT 2025 Abstract Submission & Opportunities! 1/ ๐Ÿšจ Reminder for Physicians, Data Managers, Statisticians, Psychologists, Pharmacists & Patient Advocates! You have 1 week left to submit your abstracts for #EBMT25. ๐Ÿ—“ Deadline: This Sunday! Submit here ๐Ÿ‘‰

๐ŸงตTwitter Thread:๐Ÿงต
EBMT 2025 Abstract Submission &amp; Opportunities!

1/ ๐Ÿšจ Reminder for Physicians, Data Managers, Statisticians, Psychologists, Pharmacists &amp; Patient Advocates!

You have 1 week left to submit your abstracts for #EBMT25. 

๐Ÿ—“ Deadline: This Sunday!

Submit here ๐Ÿ‘‰
Jurgen Kuball (@jkuball) 's Twitter Profile Photo

Excellent presentation of โฆChristian Chabannonโฉ on tisagenlecleucel for the Management of Patients with R/R DLBCL: an Interim Report of the European PASS Conducted by EBMT โฆEBMT_Cellular_Therapyโฉ โฆAnnalisa Ruggeriโฉ

Excellent presentation of โฆ<a href="/CChabannon/">Christian Chabannon</a>โฉ on tisagenlecleucel for the Management of Patients with R/R DLBCL: an Interim Report of the European PASS Conducted 
by EBMT โฆ<a href="/TheEBMT_CTIWP/">EBMT_Cellular_Therapy</a>โฉ โฆ<a href="/AnnalisaRugger1/">Annalisa Ruggeri</a>โฉ
IACH (@theiach) 's Twitter Profile Photo

๐ŸŒŸ Congratulations to Dr. ร‰liane Gluckman on receiving the 2024 Wallace H. Coulter Award for Lifetime Achievement in Hematology at #ASH24! A true pioneer in advancing hematology and transforming lives worldwide. youtube.com/watch?v=iqCB8eโ€ฆ Gluckman Mohamad Mohty

ASH (@ash_hematology) 's Twitter Profile Photo

The Presidentโ€™s FY26 Budget cuts NIH funding by nearly 40%. This would halt critical hematology research progress. ASH urges Congress to reject these cuts and support sustained medical research funding. Read the full statement: ow.ly/Zhns50W5IL2 #Fight4Hematology

The Presidentโ€™s FY26 Budget cuts NIH funding by nearly 40%. This would halt critical hematology research progress. ASH urges Congress to reject these cuts and support sustained medical research funding. Read the full statement:  ow.ly/Zhns50W5IL2

#Fight4Hematology
Mohamad Mohty (@mohty_ebmt) 's Twitter Profile Photo

Getting ready for #EHA2025 ? โฆIACHโฉ will be actively present in Milan with different exciting activities. Please visit our booth to learn more about our ยซย Hematology Without Bordersย ยป mantra. โฆEuropean Hematology Associationโฉ โฆThe EBMT Trainee Committeeโฉ โฆCOMyโฉ โฆ

Getting ready for #EHA2025 ?
โฆ<a href="/TheIACH/">IACH</a>โฉ will be actively present in Milan with different exciting activities. Please visit our booth to learn more about our ยซย Hematology Without Bordersย ยป mantra.
โฆ<a href="/EHA_Hematology/">European Hematology Association</a>โฉ โฆ<a href="/TheEBMT_Trainee/">The EBMT Trainee Committee</a>โฉ โฆ<a href="/COMyCongress/">COMy</a>โฉ โฆ
IACH (@theiach) 's Twitter Profile Photo

๐Ÿฉธ๐—ง๐—ต๐—ฒ ๐Ÿด๐˜๐—ต ๐—”๐—ป๐—ป๐˜‚๐—ฎ๐—น ๐— ๐—ฒ๐—ฒ๐˜๐—ถ๐—ป๐—ด ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—œ๐—”๐—–๐—› ๐—ถ๐—ป๐—ฐ๐—น๐˜‚๐—ฑ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐—–๐—ข๐— ๐˜†๐—ฑ๐—”๐—Ÿ, ๐—–๐—ข๐—Ÿ๐—ฌ๐—  ๐—ฎ๐—ป๐—ฑ ๐— ๐—ฃ๐—ก๐—–๐—ผ&๐—— ๐˜๐—ฟ๐—ฎ๐—ฐ๐—ธ๐˜€ ๐Ÿ‘‰๐—ฃ๐—ฟ๐—ผ๐˜‚๐—ฑ๐—น๐˜† ๐—”๐—ป๐—ป๐—ผ๐˜‚๐—ป๐—ฐ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐—ฅ๐—ฎ๐—ถ๐—ป๐—ฒ๐—ฟ ๐—ฆ๐˜๐—ผ๐—ฟ๐—ฏ ๐—Ÿ๐—ถ๐—ณ๐—ฒ๐˜๐—ถ๐—บ๐—ฒ ๐—”๐—ฐ๐—ต๐—ถ๐—ฒ๐˜ƒ๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฑ๐Ÿ‘ˆ

๐Ÿฉธ๐—ง๐—ต๐—ฒ ๐Ÿด๐˜๐—ต ๐—”๐—ป๐—ป๐˜‚๐—ฎ๐—น ๐— ๐—ฒ๐—ฒ๐˜๐—ถ๐—ป๐—ด ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—œ๐—”๐—–๐—› ๐—ถ๐—ป๐—ฐ๐—น๐˜‚๐—ฑ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐—–๐—ข๐— ๐˜†๐—ฑ๐—”๐—Ÿ, ๐—–๐—ข๐—Ÿ๐—ฌ๐—  ๐—ฎ๐—ป๐—ฑ ๐— ๐—ฃ๐—ก๐—–๐—ผ&amp;๐—— ๐˜๐—ฟ๐—ฎ๐—ฐ๐—ธ๐˜€

๐Ÿ‘‰๐—ฃ๐—ฟ๐—ผ๐˜‚๐—ฑ๐—น๐˜† ๐—”๐—ป๐—ป๐—ผ๐˜‚๐—ป๐—ฐ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐—ฅ๐—ฎ๐—ถ๐—ป๐—ฒ๐—ฟ ๐—ฆ๐˜๐—ผ๐—ฟ๐—ฏ ๐—Ÿ๐—ถ๐—ณ๐—ฒ๐˜๐—ถ๐—บ๐—ฒ ๐—”๐—ฐ๐—ต๐—ถ๐—ฒ๐˜ƒ๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฑ๐Ÿ‘ˆ